Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 study of MBX 2109

Next Previous
Trial Profile

A phase 3 study of MBX 2109

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canvuparatide (Primary)
  • Indications Hypoparathyroidism
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 09 Mar 2026 According to a MBX Biosciences media release, company looks forward to enrolling the first patient in Q3 2026.
  • 09 Mar 2026 According to a MBX Biosciences media release, Based on feedback from the FDA, MBX plans to advance once-weekly canvuparatide into a Phase 3 trial in the third quarter of 2026.
  • 09 Mar 2026 According to a MBX Biosciences media release, announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) to discuss the overall Phase 3 trial design for once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top